Spanish Red Biotech Pipeline

MSD

Anti CTLA-4/Pembrolizumab

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: MK-1308 in Combination with Pembrolizumab vs MK1308 alone in Subjects with Advanced Solid Tumors (Melanoma Expansion Phase)
Phase: 2Phase II in Spain, 1Phase I